Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma.

Ognjanovic S, Martel G, Manivel C, Olivier M, Langer E, Hainaut P.

Sarcoma. 2012;2012:492086. doi: 10.1155/2012/492086.

2.

The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.

Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M.

Am J Pathol. 1996 Jul;149(1):143-51.

3.
4.

TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.

Zainuddin N, Berglund M, Wanders A, Ren ZP, Amini RM, Lindell M, Kanduri M, Roos G, Rosenquist R, Enblad G.

Leuk Res. 2009 Jan;33(1):60-6. doi: 10.1016/j.leukres.2008.06.022.

PMID:
18706692
5.

KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations.

Agell L, Hernández S, de Muga S, Lorente JA, Juanpere N, Esgueva R, Serrano S, Gelabert A, Lloreta J.

Mod Pathol. 2008 Dec;21(12):1470-8. doi: 10.1038/modpathol.2008.145.

6.

Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.

Ponti F, Corsini S, Gnoli M, Pedrini E, Mordenti M, Sangiorgi L.

Fam Cancer. 2016 Oct;15(4):635-43. doi: 10.1007/s10689-016-9895-3.

PMID:
26956143
7.

The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.

Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM.

Cancer Res. 1997 Jan 15;57(2):304-9.

8.

TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors.

Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, Finlay J, Malkin D.

J Clin Oncol. 2010 Apr 20;28(12):1995-2001. doi: 10.1200/JCO.2009.26.8169.

PMID:
20308654
9.

Germline TP53 mutations and single nucleotide polymorphisms in children.

Valva P, Becker P, Streitemberger P, Lombardi GM, Rey G, Guzman CA, Preciado MV.

Medicina (B Aires). 2009;69(1 Pt 2):143-7.

PMID:
19414295
10.

Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation.

Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A.

Oncogene. 2003 Aug 14;22(34):5358-61.

PMID:
12917637
11.

Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.

Sanchez-Cespedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG, Yang SC, Jen J, Sidransky D.

Oncogene. 1999 Oct 21;18(43):5843-9.

12.

Single-Strand Conformation Polymorphism Analysis of Mutations in Exons 4-8 of the TP53 Gene.

Vähäkangas KH, Castrén K, Welsh JA.

Methods Mol Med. 2001;49:15-27. doi: 10.1385/1-59259-081-0:15.

PMID:
21370130
13.

MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.

Grünewald I, Trautmann M, Busch A, Bauer L, Huss S, Schweinshaupt P, Vollbrecht C, Odenthal M, Quaas A, Büttner R, Meyer MF, Beutner D, Hüttenbrink KB, Wardelmann E, Stenner M, Hartmann W.

Oncotarget. 2016 Nov 15;7(46):75261-75272. doi: 10.18632/oncotarget.12127.

14.

High frequency of germline p53 mutations in childhood adrenocortical cancer.

Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D.

J Natl Cancer Inst. 1994 Nov 16;86(22):1707-10.

PMID:
7966399
15.

TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.

de Anta JM, Jassem E, Rosell R, Martínez-Roca M, Jassem J, Martínez-López E, Monzó M, Sánchez-Hernández JJ, Moreno I, Sánchez-Céspedes M.

Oncogene. 1997 Dec 11;15(24):2951-8.

16.

Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D.

J Clin Invest. 1995 Apr;95(4):1606-11.

17.

High resolution melting for mutation scanning of TP53 exons 5-8.

Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ; Australian Ovarian Cancer Study Group., DeFazio A, Fox SB, Brenton JD, Bowtell DD, Dobrovic A.

BMC Cancer. 2007 Aug 31;7:168.

18.

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL.

Clin Cancer Res. 2006 Feb 15;12(4):1157-67.

19.

Analysis of TP53 germline mutations in pediatric tumor patients using DNA microarray-based sequencing technology.

Schaefer KL, Wai D, Poremba C, Diallo R, Boecker W, Dockhorn-Dworniczak B.

Med Pediatr Oncol. 2002 Apr;38(4):247-53.

PMID:
11920788
Items per page

Supplemental Content

Support Center